Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Address
3928 POINT EDEN WAY
HAYWARD, CA 94545
Founded
2015
Number of Employees
577
Website
http://www.arcusbio.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | $93 | - | - | - | - | $93 |
| Average Price | - | - | - | - | - | - | $4.22 | - | - | - | - | $4.22 |
| # Shares Purchased | - | - | - | - | - | - | 22,064 | - | - | - | - | 22,064 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | 303.1% | - | - | - | - | 303.1% |
| S&P 500 Return to Date | - | - | - | - | - | - | 74.8% | - | - | - | - | 74.8% |
| Excess Total Return | - | - | - | - | - | - | 228.2% | - | - | - | - | 228.2% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | 94% | - | - | - | - | 96% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
People also followed
Never miss an email alert when insiders at RCUS make a trade.
Creating a free account takes less than one minute